- /
- Supported exchanges
- / US
- / CTNM.NASDAQ
Contineum Therapeutics, Inc. Class A Common Stock (CTNM NASDAQ) stock market data APIs
Contineum Therapeutics, Inc. Class A Common Stock Financial Data Overview
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Contineum Therapeutics, Inc. Class A Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Contineum Therapeutics, Inc. Class A Common Stock data using free add-ons & libraries
Get Contineum Therapeutics, Inc. Class A Common Stock Fundamental Data
Contineum Therapeutics, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -65 996 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Contineum Therapeutics, Inc. Class A Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-07-30
- EPS/Forecast: -0.46
Get Contineum Therapeutics, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Contineum Therapeutics, Inc. Class A Common Stock News
New
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, wh...
Sector Update: Healthcare Stocks Ease Late Afternoon
Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc.(NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-sp...
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.